Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actinium's Actimab-A phase 2 trial is currently open for recruitment at the following centers:
Center Location
UCLA Medical Center Los Angeles, California
University of Kentucky Lexington, Kentucky
University of Louisville Louisville, Kentucky
Ochsner Medical Center New Orleans, Louisiana
Weill Medical College of New York, New York
Cornell University
Columbia University New York, New York
Medical
Memorial Sloan Kettering New York, New York
Cancer Center
Duke Cancer Center Durham, North Carolina
University of Philadelphia,
Pennsylvania Pennsylvania
St. Francis Cancer Center Greenville, South
Carolina
Baylor Scott and White Dallas, Texas
Research Institute
Swedish Cancer Institute Seattle, Washington
Fred Hutchinson Cancer Seattle, Washington
Research Center
West Virginia University Morgantown, West Virginia
Medical College of Milwaukee, Wisconsin
Wisconsin Cancer Center
VA Caribbean Healthcare San Juan, Puerto Rico
System
From 10/4 regarding Actimab- B
"We at Actinium have great confidence in our alpha-particle technology based drug candidate, Actimab-A, and in its ability to benefit patients. This Phase 2 trial in patients age 60 and older will evaluate the ability of Actimab-A to achieve remissions in these poor prognosis patients.
Sandesh Seth, Actinium's Chairman and Chief Executive Officer said, "CD33 is a validated target in AML and in our experience a resurgent area of interest amongst the medical community post the recent reapproval of Mylotarg. Importantly, the CD33 space that continues to garner much interest as evidenced by recent drug approvals, strategic transactions and a robust development pipeline represented by several major pharmaceutical and biotechnology companies. We believe that Actimab-A has the potential to be best in the CD33 class given the combination of its potency as a single agent, its relatively simple administration via two injections, and its relative benign safety profile. We look forward to updating by year-end on the significant progress we are making with the Actimab-A trial."
Dr. Mark Berger, Actinium's Chief Medical Officer said, "I am delighted to be working with these world-renowned investigators and institutions in this important SIERRA trial for Iomab-B. Their interest and enthusiasm for Iomab-B further motivates my team as we work on this trial to bring Iomab-B to patients who could benefit from safer myeloablation prior to a bone marrow transplant.
The following medical institutions are clinical trial sites in the Iomab-B Phase 3 clinical trials:
Center Location
MD Anderson Cancer Center Houston, Texas
Memorial Sloan Kettering Cancer Center New York, New York
Mayo Clinic Rochester, Minnesota
Mayo Clinic Jacksonville, Florida
Washington University School of Medicine Saint Louis, Missouri
Yale Cancer Center New Haven, Connecticut
Baylor Charles A. Sammons Cancer Center Dallas, Texas
The University of Kansas Cancer Center Westwood, Kansas
Roswell Park Cancer Institute Buffalo, New York
University Hospitals Cleveland Medical Center Cleveland, Ohio
The Ohio State University Comprehensive Cancer Columbus, Ohio
Center
Penn State Hershey Cancer Institute Hershey, Pennsylvania
Loyola University Medical Center Maywood, Illinois
Banner MD Anderson Cancer Center Gilbert, Arizona
Fred Hutchinson Cancer Research Center Seattle, Washington
"Actinium intends to build on the clinical experience, infrastructure and supply chain capabilities that we have established thus far to complete the trial in accordance with prior guidance and, assuming a successful outcome, establish Iomab-B as the standard of care in providing safer myeloablation first in in AML and then in the other hematologic indications in which it has shown positive results."
From the CEO - "There is no visible competition for Iomab-B from any drug or drug candidate that can provide safer myeloablation and enable improved outcomes of bone marrow transplant.
More from the PR
"These fifteen centers perform approximately a third of all AML related bone marrow transplants. Our ability to introduce Iomab-B in these centers bodes well for enrollment in the trial and also the commercial opportunity for Iomab-B as the top fifty centers account for approximately eighty percent of bone marrow transplants."
From the Latest PR -
"In many blood cancers and disorders a bone marrow transplant is the only potentially curative treatment option for patients and it is our goal to improve outcomes for these patients with Iomab-B by getting them to their transplant faster and with less complications than currently available myeloablative regimens allow."
Radio-immunotherapy: attacking cancer from within (Mentions and reviews Targeted Alpha therapy TAT in a very positive light. Old article but very relevant and informative)
http://medicalphysicsweb.org/cws/article/opinion/53719
Radio-immunotherapy: attacking cancer from within (Mentions and reviews Targeted Alpha therapy TAT in a very positive light. Old article but very relevant and informative)
http://medicalphysicsweb.org/cws/article/opinion/53719
I agree with you - lots of new mutual funds also in the picture now!
Trump just dropped a big hint to the pharmaceutical industry
https://www.washingtonpost.com/news/wonk/wp/2016/11/14/trump-just-dropped-a-big-hint-to-the-pharmaceutical-industry/
Very interesting -
John Pagel, M.D., Ph.D. discussing Iomab-B for HSCT (bone marrow transplant) in Older Patients with Relapsed/Refractory Acute Myeloid Leukemia
Joseph Jurcic, M.D. discussing Iomab-B in Refractory AML: can older patients with active disease be transplanted?
http://ir.actiniumpharma.com/video-gallery
Factsheet Oct 2016
http://c.eqcdn.com/_a959cbe04805104db28ff6e79a1d5597/actiniumpharma/db/206/775/pdf/ATNM+Fact+Sheet+October+2016.pdf
"Several ongoing physician trials with BC8 mAb, the antibody used in lomab-B, for other indications.
Safety and efficacy data to date indicate that Iomab-B can potentially disrupt the field of BMT"
"The $1.3 billion BMT market in the U.S. is largely unaddressed by novel pharmaceutical companies.
Approximately 150 centers perform approximately 20,000 BMT procedures in the U.S. annually.
Top 30 centers perform greater than 50% of all AML BMT procedures"
pg 15
Actinium is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. Our most advanced products are Actimab™-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab™-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. We initiated the pivotal Phase 3 trial of Iomab™-B for bone marrow conditioning for HSCT in relapsed and refractory AML patients’ age of 55 and older, which upon successful completion of our clinical trials we intend to submit for marketing approval. We are currently also considering filing an application with the U.S. Food and Drug Administration (FDA) for breakthrough therapy designation for Actimab™-A and/or Iomab™-B.[b We are developing our cancer drugs using our expertise in radioimmunotherapy. In addition, our Ac-225 based drug development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC), a significant stockholder in our company. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213. The final drug construct is designed to specifically target and kill cancer cells while minimizing side effects. We intend to develop a number of products for different types of cancer and derive revenue from partnering relationships with large pharmaceutical companies and/or direct sales of its products in specialty markets in the United States.
pg 6 (broadening the use of Ac225!)
On September 30, 2014, the Company entered into a research agreement with the Albert Einstein College of Medicine of Yeshiva University (“Einstein”). According to the agreement, Einstein will use certain materials provided by the Company to complete a research project. The research project will explore the feasibility of using Actinium 225 to prepare patients with blood borne cancers to receive a hematopoietic stem cell transplant. Einstein will periodically provide the Company with reports showing project data or research. The total fixed price of the project is $0.2 million which is payable to Einstein in three payments.
During the nine months ended September 30, 2016 and 2015, the Company paid Einstein approximately $37,000 and $55,000, respectively in full of the agreement.
Pg 6
On December 16, 2015, the Company announced that the FDA cleared the Company's IND filing for Iomab-B, and that it will proceed with the pivotal, Phase 3 clinical trial. In June 2016, Actinium announced the pivotal Phase 3 clinical trial for Iomab-B was initiated and assuming that the trial meets its end points, it will form the basis for a Biologics Licensing Application (BLA) with the FDA. The Company, in its recently approved IND filing, established an agreement with the FDA that the path to a Biologics License Application submission would include a single, pivotal Phase 3 clinical study if it is successful. The population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed AML patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and a secondary endpoint that will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physicians sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in almost 300 patients have demonstrated the potential for Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.
pg 26
There are limited quantities of Ac-225 available today. The existing supplier of Ac-225 to us is the ORNL, which is a science and energy national laboratory in the Department of Energy system. ORNL manufactures Ac-225 by eluting it from its supply of Thorium-229. Although this has proven to be a very reliable source of production for a number of years, it is limited by the quantity of Thorium-229 at ORNL. We believe that the current approximate maximum of Ac-225 production from this source is sufficient for approximately 1,000–2,000 patient treatments per year. Since our needs are significantly below that amount at this time, and will continue to be below that for as long as we do not have a commercial product with a potential of selling more than 2,000 patient doses per year, we believe that this supply will be sufficient for completion of clinical trials and early commercialization. To secure supplies beyond this amount, we have developed what we believe to be a scalable cost-effective process for manufacturing Ac-225 in a cyclotron at an estimated cost in excess of $5 million. This work has been conducted at Technical University Munich (TUM) in Germany. We are now in possession of detailed descriptions of all the developed manufacturing procedures and have rights to all relevant patent applications and other intellectual property. However, we do not currently have access to a commercial cyclotron capable of producing medical grade Ac-225. Although beam time on such cyclotrons is commercially available, we do not currently have a relationship with any entity that owns or controls a suitable cyclotron. We have identified possible sources and estimate that we could secure the necessary beam time when needed at a cost of approximately $2 million per year.
Today's filing pg22
We currently have only two products in clinical development. We have commenced a Phase 1/2 multi- center AML trial with fractionated doses of Actimab™-A under its own federal Investigational New Drug Application (IND). Additionally, there are a number of physician IND trials at the FHCRC that have been conducted or are currently ongoing at FHCRC with single doses of Iomab™-B. In December 2015, the FDA cleared our IND filing for Iomab-B, and that we will proceed with the pivotal, Phase 3 clinical trial. In June 2016, we announced the pivotal Phase 3 clinical trial for Iomab-B was initiated and assuming that the trial meets its end points, it will form the basis for a Biologics Licensing Application (BLA).
site not updated
http://www.sart.org/SARTExecutiveCouncil/
News & Publications: News & Research › Press Releases ›
October 19 , 2016
by: ASRM Office of Public Affairs
Published in ASRM Press Release
Note: Press room open Sun. October 16, 2pm-5pm MDT; Mon. October 17-Wed. October 19 8:00am-5:30pm MDT. (801) 534-4704
Salt Lake City- The American Society for Reproductive Medicine is pleased to announce the 2016-2017 leaders of its affiliated societies.
Society for Assisted Reproductive Technology
SART is the primary organization of professionals dedicated to the practice of assisted reproductive technologies (ART) in the United States. ART includes the practice of In Vitro Fertilization (IVF). The mission of our organization is to set and help maintain the standards for ART in an effort to better serve our members and our patients.
Serving as President, Kevin Doody, MD of the Center for Assisted Reproduction, Bedford, TX.
Serving as President-elect: David Seifer, M.D. of Dartmouth
Society of Reproductive Surgeons (SRS)
The Society of Reproductive Surgeons was founded in 1984 to serve as a forum for members of the American Society for Reproductive Medicine with special interest and competency in reproductive surgery.
Serving as President: Ceana H. Nezhat, M.D. of the Nezhat Medical Center, Atlanta, GA
Serving as President-elect: Samantha Pfeifer, M.D. of Cornell University
Society of Reproductive Biologists and Technologists (SRBT)
The mission of SRBT is to advance the continuous professional development of scientists and laboratory specialists working in all disciplines of Reproductive Biology and applied Assisted Reproductive Technologies (ART). SRBT promotes standards of excellence in research and laboratory applications.
Serving as President: Andrew Dorfmann, M.S. from Genetics & IVF Institute in Fairfax, VA
Serving as President-elect: Arthur Chang, Ph.D., HCLD/ELD/CC of the University of Texas
Society for Male Reproduction and Urology (SMRU)
The mission of SMRU is to promote the advancement of our understanding of male reproductive physiology and management of male infertility by providing a forum for the dissemination of both basic and clinical research information and support of educational programs.
Serving as President: Dan Williams, MD of the University of Wisconsin
Serving as President-elect: Cori Tanrikut, MD of Massachusetts General Hospital
Society for Reproductive Endocrinology and Infertility (SREI)
SREI Membership requires certification by the American Board of Obstetrics and Gynecology in both Obstetrics and Gynecology and the subspecialty of Reproductive Endocrinology. Associate Members are completing or have completed fellowship training in Reproductive Endocrinology, and are waiting to complete the Subspecialty Board Examination process.
Serving as President: Tom Price, MD of Duke University
Serving as President-elect: Larry Layman, MD of Georgia Regents University
BooDog,
what does below 10% mean?
Craig Sager’s cancer fight continues with rare third bone marrow transplant
http://sports.yahoo.com/news/craig-sagers-cancer-fight-continues-with-rare-third-bone-marrow-transplant-163346931.html
Craig Sager clarifies his 3-6 months to live cancer prognosis, vows to 'win this battle'
http://www.nydailynews.com/sports/basketball/craig-sager-clarifies-3-6-months-live-cancer-prognosis-article-1.2574672
Biden outlines 'Moonshot' initiatives to fight cancer
https://www.yahoo.com/news/biden-outlines-moonshot-initiatives-fight-cancer-164117399.html
"Among proposals intended to bypass inefficiency at the federal level, he announced the formation of an Oncology Center of Excellence at the Food and Drug Administration, which will coordinate and review all of FDA cancer treatments."
This should only help ATNM
Cancer moonshot unveils panel of advisers
http://thehill.com/policy/healthcare/275081-cancer-moonshot-unveils-panel-of-advisors
Cancer moonshot unveils panel of advisers
http://thehill.com/policy/healthcare/275081-cancer-moonshot-unveils-panel-of-advisors
NFL official finally admits link between football, trauma and CTE
https://www.yahoo.com/sports/blogs/nfl-shutdown-corner/nfl-official-finally-admits-link-between-football-and-cte-011805486.html
With FDA settlement, tiny Amarin creates opening for pharma in off-label marketing
http://www.fiercepharma.com/story/fda-settlement-tiny-amarin-creates-opening-pharma-label-marketing/2016-03-09?utm_medium=nl&utm_source=internal&mrkid=%257B%257Blead.Id%257D%257D&mkt_tok=3RkMMJWWfF9wsRokuaXJd%252B%252FhmjTEU5z16u0lWaa3ipZ41El3fuXBP2XqjvpVQcdqML%252FMRw8FHZNpywVWM8TILtkUt9hsLQziDW0%253D
Lassa fever has killed more than 100 in Nigeria, latest figures show
http://www.theguardian.com/world/2016/feb/06/lassa-fever-has-killed-more-than-100-in-nigeria-latest-figures-show
American with suspected Lassa fever coming to U.S. Ebola unit for treatment
http://www.cnn.com/2016/03/11/health/lassa-fever-emory-atlanta/index.html
Women Can Now ‘Grow’ Their Own IVF Embryos with In-Body Incubator
http://futurism.com/women-can-now-grow-ivf-embryos-body-incubator/
INVOcell – the way to cheaper IVF?
http://www.eggdonationfriends.com/invocell-the-way-to-cheaper-ivf/
INVOcell Could Bring IVF Treatment to Millions
http://globalbioethics.org/2016/01/invocell-could-bring-ivf-treatment-to-millions/
Women can ‘grow’ their own IVF embryos with in-body incubator
https://www.newscientist.com/article/mg22930554-500-women-can-grow-their-own-ivf-embryos-with-in-body-incubator/
Doctors: Upsurge in paralysis condition accompanies Zika
Doctors: Upsurge in paralysis condition accompanies Zika
CUCUTA, Colombia (AP) — The doctor taps Zulay Balza’s knees with a hammer and she doesn’t feel a thing. She can’t squeeze his outstretched fingers or shut her eyelids. Her face is partially paralyzed.
10 Best Cards: Free Transfers, 0% intro APR, $400
CompareCards.com Sponsored
? ?
“The weakness started in my legs and climbed upward. The face was last. After three days, I couldn’t walk,” said Balza, 49. “My legs felt like rags.”
Balza is a patient at the public University Hospital in Cucuta, at the epicenter of the Colombian outbreak of the mosquito-borne Zika virus. Only Brazil has more cases.
Two weeks ago, she came under assault by Guillain-Barre (gee-YOHN-bah-RAY), a rare and sometimes fatal affliction that is the Western world’s most common cause of general paralysis.
Alarm over the Zika epidemic spreading across the Americas has been chiefly over birth defects, but frontline physicians believe a surge in Guillain-Barre cases may also be related.
The World Health Organization says Guillain-Barre cases are on the rise in Brazil, Colombia, El Salvador, Suriname and Venezuela, all hit hard by Zika, though a link remains unproven.
The auto-immune disorder historically strikes only one or two people in 100,000. About one in 20 of those cases ends in death in the developed world, and it is frightful.
“I thought my body was going to explode,” said Balza, sitting on her hospital bed and apparently over the worst.
Guillain-Barre attacks skeletal muscular nerves as if they were a foreign enemy. Fine motor skills rapidly erode, arms and legs tingle and weaken to numbness. Patients lose their balance, their speech. In rare cases, they require ventilators to stay alive.
The syndrome typically strikes after a bacterial or viral infection, such as influenza, HIV or dengue, though its cause can’t always be determined.
Dr. Jairo Lizarazo, the neurologist treating Balza, has seen cases increase more than tenfold since December — 30 cases in all — in this muggy city bordering Venezuela. Like Balza, many patients never showed the characteristic symptoms of Zika — fever, rashes, joint pain and conjunctivitis. Four in five don’t.
He’s convinced the virus boosts susceptibility to Guillain-Barre.
“It’s an epidemiological association,” said Lizarazo. “We don’t know exactly how it works. But it’s there, for sure.”
Associated cases confirmed or suspected based on clinical evidence number in the hundreds. Guillain-Barre cases believed to be linked to the virus have killed three people in recent weeks in Colombia and health officials have attributed another three Guillian-Barre deaths in Venezuela to suspected Zika infections.
WHO said Zika has been confirmed present in apparently just one Guillain-Barre death, in the northwestern Venezuela state of Zulia in January.
Dr. Maria Lucia Brito Ferreira, chief neurologist at Hospital da Restauracao in Recife, Brazil, said she hopes to get laboratory confirmation this month that nine Guillain-Barre deaths recorded there in the past year were Zika-related.
Cases of Guillain-Barre in Colombia — about 450 annually before Zika struck — were up nearly threefold in the past month and a half.
El Salvador has reported 118 cases since November, nearly as many as previously seen in a year. “The only explanation is the Zika virus,” said Deputy Health Minister Eduardo Espinoza.
Dr. Osvaldo Nascimento, a leading Rio neurologist, estimates Brazilian cases of Guillain-Barre are up fivefold. Reporting is not compulsory, so the government’s partial figure of 1,868 cases requiring hospitalization last year is a sketchy parameter.
An upsurge in Guillain-Barre was documented in 2013 during a major Zika outbreak in French Polynesia, with a study finding cases up twentyfold. WHO said all 42 cases recorded in the Pacific archipelago tested positive for Zika as well as dengue fever, which is also currently present in Colombia, Venezuela, Brazil and other Zika-affected countries.
Antibodies for the dengue and chikungunya viruses, which are far more debilitating than Zika, are often being found in infected patients. That is making establishing a direct Zika-Guillain-Barre link more complicated.
Like Zika, both viruses are transmitted by the Aedes aegypti mosquito and could also trigger Guillian-Barre, experts say.
Under normal circumstances, eight in 10 patients nearly fully recover from Guillian-Barre, though it sometimes takes months.
Data on Guillain-Barre is scant in most of the developing world. Of 18 countries participating in a clinical study launched by Dutch physicians in 2012, only two are in Latin America: Mexico and Argentina. Brazil just joined.
Across the region, investigators were simply unable to get government funding to participate, said Dr. Ken Gorson, a Tufts University neurologist and president-elect of an international foundation that combats Guillain-Barre.
Poorer countries were ill-prepared to manage the crisis.
Colombia’s National Health Institute is overwhelmed with a weeks-long backlog in completing tests for Zika.
The three Guillain-Barre deaths that the country’s Health Ministry attributed to Zika on Feb. 5 have not yet been confirmed by laboratory tests, said spokesman Ricardo Amortegui. Nor have the three deaths in the Venezuelan state of Lara announced last week.
One Guillian-Barre fatality in Colombia suspected of being linked to Zika was a 51-year-old man from the Caribbean island of San Andres who died in November, said Rita Almanza, epidemiology chief in Medellin. The others were a 45-year-old man and a 41-year-old woman flown from Turbo on the Caribbean coast who died in Medellin in February.
Guillain-Barre grabbed hold of Nancy Pino in neighboring Venezuela with devastating effect.
The 68-year retired school administrator developed fever, rashes and muscle pain while celebrating Christmas with her family in the hot lowland state of Anzoategui.
She recovered quickly. Days later, her hands and feet started to go numb. Her tongue felt like it was asleep. She stopped eating.
The family rushed her to a Caracas hospital. She could barely walk.
Bed-ridden, she lost the ability to talk and soon, to breathe. Doctors attached her to a respirator.
“It was so quick,” daughter Nihara Ramos said between sobs. “It was like a flame consuming her from the bottom up.”
Doctors diagnosed Guillain-Barre with a spinal tap — they assumed she had Zika earlier — and suggested that the relatives obtain immunoglobulin, an expensive treatment that pools healthy antibodies from hundreds of donors. Gorson said it costs $15,000-$45,000 in the United States.
The family, straightjacketed by Venezuela’s economic crisis, couldn’t find or afford enough.
In less than three weeks, a woman who once bounded up seven flights of stairs to her apartment was dead.
___
Associated Press writer Frank Bajak reported this story from Lima, Peru, and AP writer Libardo Cardona reported in Cucuta, Colombia. AP writers Hannah Dreier in Caracas, Venezuela; Marcos Aleman in San Salvador, El Salvador; and Luis Henao in Santiago, Chile, contributed to this report.
Zika fears spur pharmaceutical gold rush - mentions AEMD
http://seekingalpha.com/news/3107556-zika-fears-spur-pharmaceutical-gold-rush?app=1#email_link
Hawaii declares emergency over mosquito-borne illnesses
http://medicalxpress.com/news/2016-02-hawaii-declares-emergency-mosquito-borne-illnesses.html
The enduring need for cancer treatment
http://medicalxpress.com/news/2016-02-cancer-treatment.html
http://www.protectthebrain.org/Our-Research.aspx
"Understanding Our Scientific Research
Studying the Effects of a Traumatic Brain Injury
At the Brain Injury Research Institute, we have found a clear link between brain injuries and various neurological disorders—including Alzheimer's disease and other forms of dementia. One of the most common neurological disorders is Mild Traumatic Brain Injury (MTBI), which is more commonly referred to as a concussion. This can occur when a swift impact or sudden forceful motion of the head causes a brief alteration of mental status, which can materialize in confusion, loss of consciousness, disorientation and loss of memory of the events occurring immediately before or after the injury.
When a person suffers multiple concussions, which is common among athletes, they can develop a disease known as chronic traumatic encephalopathy (CTE). Also known as dementia, pugilistica or "punch-drunk" syndrome, this disorder commonly manifests as declining mental ability, problems with memory and parkinsonism, which causes tremors and lack of coordination. Our primary focus is to research the effects of CTE, as it is not uncommon for a patient with this disease to be prone to inappropriate or explosive behavior and displays of pathological jealousy or paranoia.
While it was first discovered that boxers are susceptible to this disease, CTE has also appeared in football players and other athletes. Additionally, studies have shown that traumatic brain injury is the second most common injury sustained by the U.S. troops who were involved in Operation Iraqi Freedom and Operation Enduring Freedom. Research indicates that it could lead to cases of CTE. It is for this reason that the Brain Injury Research Institute is committed to researching the effects of this disease and, ultimately, finding a cure. If you are interested in getting involved, we encourage you to learn more by clicking here."